MDWD (mediwound.com) Short-Term Debt to Capital

Current price action for MediWound Ltd. (MDWD) demonstrates metrics where the value is 0.01. MediWound Ltd. (MDWD) develops biopharmaceutical products for the automatic cleansing of skin lesions, eliminating the need for manual surgical intervention by physicians. Business revenues are based on the sale of enzymatic agents that remove necrotic tissue in ulcers. However, slow sales growth for NexoBrid in the US and a dependence on BARDA contracts create financial risks.

MediWound Ltd. maintains a dominant position in the enzyme burn therapy segment thanks to exclusive FDA statuses. This ratio correlates liabilities with a maturity of up to one year to total equity, measuring the company's dependence on short-term debt financing. It is critical for investors to distinguish between a temporary liquidity shortage and a systemic solvency crisis. Analyzing the historical trend of short-term debt to equity allows for an assessment of the business's financial stability amidst market expansion.